The 2002 paper that scared a generation off HRT was wrong. Not all of it. The piece of it that mattered most, the piece every news headline ran with, the piece that moved roughly a million American women off hormone therapy in twelve months. That piece was wrong. The data that showed it was wrong was already in the same trial.
Monday named the math for women in the deposit decade. Ten percent spine bone loss across the transition. Thirty percent strength gone by 60 if untrained. One in two unable to get off the floor unassisted by 80. The single most effective intervention for that window is hormone therapy. The reason most women in this band have never been offered it goes back to one trial, one press conference, and one set of numbers that should have been read as small and were read as large.
The harm was not in the prescribing. The harm was in twenty years of avoidance. Find your Healthspan Score →
The card shows: HT 27.1% vs placebo 27.6% (18-yr mortality, Manson 2017); 50-59 (the age band the trial design targeted); 7 per 10K (excess CHD per 10,000 woman-years, Rossouw 2002).
Save this. Three numbers the 2002 headlines did not lead with.
What The Research Actually Says
The 2002 paper. Rossouw et al, JAMA, the principal results of the Women's Health Initiative estrogen-plus-progestin arm. 16,608 postmenopausal women, aged 50 to 79, randomised to combined hormone therapy or placebo. The trial was stopped early at 5.2 years average follow-up because the relative risk numbers crossed the predefined boundary. The absolute numbers told a much smaller story. Per 10,000 woman-years: 7 more coronary events, 8 more strokes, 8 more pulmonary embolisms, 8 more invasive breast cancers, against 6 fewer colorectal cancers and 5 fewer hip fractures. The headlines did not lead with the per-10,000 framing. They led with the early stop.
Before the conversation, the baseline. Find your Healthspan Score →
The reanalysis. Manson et al, JAMA 2013, 27,347 women across both WHI arms, 13 years of cumulative follow-up, stratified by age at initiation. The risk-benefit pattern fell apart by age band. Women aged 50 to 59 at initiation, the band the trial design was originally written to target, carried a different absolute risk profile than the women aged 70 to 79 at initiation. The 70-to-79 band was the part of the cohort driving the harm signal. Most clinicians treating menopausal symptoms are not treating 70-year-olds initiating HT for the first time. They are treating women aged 48 to 55 in the perimenopausal window. The trial's pooled result did not reflect the patient population.
The long follow-up. Manson et al, JAMA 2017, 18 years of mortality data on the same 27,347 women. All-cause mortality, hormone therapy group: 27.1 percent. All-cause mortality, placebo: 27.6 percent. The pooled difference was not statistically significant. Use of hormone therapy for 5 to 7 years did not increase all-cause, cardiovascular, or cancer mortality across 18 years of follow-up. That is the single most important sentence in this piece.
The consensus. The North American Menopause Society's 2022 Hormone Therapy Position Statement, updating its 2017 statement, drew the direct conclusion. For most healthy symptomatic women under 60 within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks. ACOG Practice Bulletin 141, originally issued in 2014 and reaffirmed in 2024, names systemic estrogen therapy as the most effective treatment for vasomotor symptoms. Both documents endorse the timing-hypothesis frame the 2013 reanalysis established.
The Bottom Line
This piece is the other side of the brand's anti-pharma stance. The brand argues against statins for low-risk primary prevention. Against SSRIs as a first move for mild depression. Against PPIs as a chronic prescription. Against the over-prescription patterns the wellness internet has named for years. Anti-pharma-bias is not anti-medicine. The same lens that calls out over-prescription calls out misinformed avoidance. In hormone therapy for women in the timing window, the harm was not in the prescribing. The harm was in twenty years of clinicians being too cautious to offer it, and twenty years of patients being too afraid to ask.
Find a clinician who reads the post-2013 literature. The NAMS practitioner directory is the editorial starting point. Ask about the timing-hypothesis frame. Ask about your specific risk profile. The decision is yours; the information being on the table is the brand's editorial point.
Friday Preview
Three concrete behaviours to lock in for the next decade. DEXA at 40 to set the baseline. Protein floor at 1.6 grams per kilogram. Two resistance sessions a week, every week. None of them require a prescription. All three compound. Friday.
Until Friday.
Longevity Daily · The Building Decades
Share this edition with someone you love.